

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED**

**銘源醫療發展有限公司\***

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 0233)**

**QUARTERLY UPDATE ON TRADING SUSPENSION**

This announcement is made by Mingyuan Medicare Development Company Limited (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09(2) and 13.24A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the provisions of inside information under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement dated 15 July 2015 regarding the resumption conditions (the “Resumption Conditions”) imposed on the Company, the announcement dated 18 April 2019 regarding further resumption guidance (the “Further Resumption Guidance”) and the announcements dated 10 August 2018, 6 November 2018, 11 February 2019 and 2 May 2019 on the updates on trading suspension (the “Quarterly Updates”).

Terms defined in the aforementioned announcements shall have the same meaning herein unless otherwise defined or the context otherwise required.

**UPDATE ON RESUMPTION CONDITIONS**

On 3 July 2019, the Company had formally submitted its application for resumption of trading of the Company’s shares to the Hong Kong Exchanges and Clearing Limited (the “HKEX”). By way of a letter dated 16 July 2019, the HKEX set out their observations and guidance in response to the Company’s application, and the Company had subsequently addressed some of these observations and guidance. Thereafter, there are on-going exchanges of views by correspondences between the HKEX and the Company. The Company will make further announcements of any material development as and when appropriate.

*\* For identification purpose only*

## **UPDATE ON BUSINESS OPERATION**

As at the date of this announcement, GPSZ has been carrying on its business as usual. In relation to the business operated/controlled by the two Shanghai subsidiaries, Shanghai HealthDigit and SHMY Biochip, the Board is unable to provide information on their operation given that the Company is still in the process of regaining its control over these two key subsidiaries.

## **CONTINUED SUSPENSION OF TRADING**

The Company will keep its shareholders and potential investors informed of any material development in connection with the resumption progress, by way of quarterly announcements and/or further announcements as and when appropriate.

By Order of the Board  
**Mingyuan Medicare Development Company Limited**  
**LAM Ping Cheung**  
*Chairman*

Hong Kong, 2 August 2019

*As at the date of this announcement, the Board comprises (i) Mr. Lam Ping Cheung and Mr. Hui Yip Wing as executive Directors and (ii) Ms. Chan Mee Sze, Mr. Lam Suk Ping, Ms. Fan Stephanie Winnie and Mr. Cheung Chi Ming as independent non-executive Directors.*